POPULARITY
Categories
140 episodes with msd
101 episodes with msd
29 episodes with msd
214 episodes with msd
16 episodes with msd
17 episodes with msd
8 episodes with msd
11 episodes with msd
5 episodes with msd
12 episodes with msd
4 episodes with msd
7 episodes with msd
6 episodes with msd
4 episodes with msd
4 episodes with msd
12 episodes with msd
4 episodes with msd
4 episodes with msd
3 episodes with msd
5 episodes with msd
3 episodes with msd
4 episodes with msd
4 episodes with msd
2 episodes with msd
3 episodes with msd
3 episodes with msd
3 episodes with msd
4 episodes with msd
3 episodes with msd
6 episodes with msd
3 episodes with msd
2 episodes with msd
5 episodes with msd
2 episodes with msd
2 episodes with msd
3 episodes with msd
#7 and #8 Prevail, MSD is Tight, Week 16 NFL recap - Episode #913
What if measuring worm resistance didn't require high parasite burdens and ALSO delivered double the heritability of egg counts?Sarah Preston, Lecturer at Federation University and cofounder of Swabtec, explains the development of their saliva-based test designed to measure immune responses to gastrointestinal worms in sheep, allowing resistance to be assessed without relying on high worm egg counts.She and Mark discuss why egg counts often fail to reflect adult worm burden, particularly in mixed infections and with species that regulate egg production, and how this affects breeding and management decisions in well-managed, low challenge systems.They also discuss where they are with the development and validation of Swabtec. They are currently working to validate the test across breeds and environments and are planning to develop breeding values as the data builds. The test has been found to have a heritability of 0.4 compared to the WEC of 0.2 meaning flock improvements based on insights and data from Swabtec can occur twice as fast!Find out more below:https://swabtec.com/Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
The Big Unlock · Gregory Goldmacher, M.D., Associate Vice President in Clinical Research, and Head of Clinical Imaging & Pathology, Merck Research Laboratories In this episode, Dr. Greg Goldmacher, Associate VP of Clinical Research at Merck, known as MSD outside of the United States and Canada, explains how AI is transforming imaging, clinical trials, and early-stage drug development. Greg describes endpoints as the core of every clinical trial, since they determine whether a therapy is safe or effective. He notes that AI is not new to imaging and aligns well with pattern recognition, yet its real value lies in identifying details that humans often miss. Greg stresses that drug development still depends on huge volumes of data spread across legacy systems. Without strong data standardization, AI cannot deliver reliable results. He also points to the FDA's evolving guidance on AI and emphasizes the need for rigorous validation before using AI-derived measurements for regulatory decisions. Greg highlights the opportunity to improve efficiency, reduce human burden, and generate more consistent insights. With thoughtful adoption, AI can support better decisions in clinical development and improve outcomes for patients. Take a listen.
A woman fears her son could be severely traumatised if he finds out the Ministry of Social Development published information about his abuse in state care compensation application online. He's one of five people whose names were visible in an MSD Official Information Act document that was left online for three months. None of the five abuse survivors have been told about the breach, and there's disagreement between MSD and the survivors' lawyers about how they should be informed. Jimmy Ellingham reports.
This episode of MSD features a conversation with Rob Sinn about market psychology and key themes heading into 2026. The Trevor and Rob analyze the recent consolidation mode in precious metals, noting that gold has been consolidating below the $4,400 resistance level after a correction back in October. A major topic of speculation is the appointment of the next Federal Reserve Chairman, with the choice between Warsh and Hassett expected to significantly impact the trajectory of metals and mining markets, potentially leading to varied levels of rate cuts and market corrections. The conversation also covers investment themes like the projected loss of Federal Reserve autonomy and the quiet nature of tax-loss selling in 2025, while highlighting specific mining stocks like Ramp, Aztec, and Talon Metals that possess strong potential catalysts for the new year.
What if the biggest risk in pharma wasn't bold innovation — but staying exactly where we are?This conversation with Marc Gailhardou challenged the way I see leadership, growth, and purpose in a world that never stops shifting.Marc is the President of MSD's EEMEA region and board member of the digital-health startup Resilience. With a career built on bold transitions between global headquarters and local markets, Marc brings a unique mix of strategic depth, operational clarity, and genuine human insight.Together, we explore how he navigates one of the most complex regions in global health, what emerging markets can teach mature systems, how purpose guides career decisions, and why clarity, courage, and connection matter more than ever.What you'll hear in this episode:◾️ What it really means to lead 25% of the world's population◾️ The mindset shift that changes everything in so-called “emerging” markets◾️ Why distance helped him see Europe more clearly◾️ The hidden tension between global vision and local reality◾️ A radically different way to think about career risk◾️ The one leadership question that has guided him for 20 years◾️ What stepping into a startup taught him◾️ Why trust in pharma requires more nuance than strength or vulnerability aloneI invited Marc because of his remarkable ability to listen, his humility, his eagerness to learn from others, and his entire set of talents needed to thrive in a transforming world. This is a leader you need to hear — urgently.Tune in and let Marc shift the way you think about leadership in pharma.—Find Marc Gailhardou: LinkedIn: https://www.linkedin.com/in/marc-gailhardou-aa51811/?originalSubdomain=ch—Resources mentioned in the episode:
What limits ewe productivity in current sheep systems?Our guest this week, Tara Dwyer is breeding manager at Headwaters Genetics and a farm manager within the Lone Star Farms group. Her work covers stud breeding, commercial supply chains, and large-scale sheep systems, and in amongst all of that, she found time to do a Kellogg report, "A New Fleece on Life: How the Sheep Farming Sector in Aotearoa Can Halt Terminal Decline to Secure a Sustainable and More Secure Future"Starting with her "day job", Tara and Mark discuss the value of genetics within a value chain, and how Headwaters is focusing on eating quality traits alongside maternal performance, resilience, and low-input efficiency. Tara explains how and why Headwaters selects for intramuscular fat and fatty acid profiles while still prioritising reproduction, lamb survival, and health traits.Mark and Tara then discuss her recent Kellogg report, which looks at why lambs weaned per ewe have barely shifted for decades, why carcass output improved while reproduction stalled, and why relying on ram breeders alone is not a reproductive strategy. Tara explains her findings on where current systems have plateaued, what existing technology already allows producers to measure, and why individual ewe performance will be one of the next major productivity levers.If you're interested in getting involved in the Head Shepherd TwentySix2000 campaign, click the link below:https://fundraise.curebraincancer.org.au/fundraisers/markferguson/twentysix2000Strava link:https://www.strava.com/clubs/1858801Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
The real risk isn't failure — it's never fulfilling your purpose.In this short preview, Marc Gailhardou, President of MSD's EEMEA region, shares a perspective that can reframe your entire career.He explores why a long-term mindset, resilience, and the courage to move when “the necessary departure” calls are essential for anyone who wants to grow in the pharma world.
This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies.Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial.Studies:LITESPARK-15IMPRESS-Norway trialAbstract 1510M0BNT111 (NCT04526899)Safe Stop TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Episode 3164 of the Vietnam Veteran News Podcast will feature a story about MSD and how it effects Vietnam Veteran. The featured story is titled: Agent Orange Linked To Rare Bone Marrow Cancers. It appeared on the U.S. News website … Continue reading →
We have a trade in MSD, TNF and Sunday AM Previews and a quick glance at the 2 MSD Matchups - Episode #906
MSD discusses the latest developments at Collective Mining with Chairman Ari Sussman. They delve into the recent drilling results from the Ramp Zone, highlighting the significant gold grades found and the ongoing exploration efforts. The conversation also covers the discovery of a new hanging wall vein system, the implications for future mining operations, and the company's strategic plans for 2026, including a substantial drilling program and the potential for a mineral resource estimate.
Gus Rose shares the recent results from the 'Genetics of foot health in Merinos' project, which is looking at footrot and foot structure in sheep in Australia. Gus shares what the data shows on the heritability of foot shape and its relationship with footrot, as well as other foot structure traits. Gus Rose explains how the dataset is being built, which traits are proving to be correlated, and where the current limits sit. Gus and Mark discuss the project's future and the significance of the results for the industry. If you would like to know more about how to get involved, please email Amy at amy@nextgenagri.comThe project is funded by Australian Wool Innovation, Animal Health Australia and collaborating Merino breeders, and is being conducted by Murdoch University and neXtgen Agri in collaboration with AGBU and SheepMetrix. You can view our webinar here:https://thehub.nextgenagri.com/c/articles/live-genetics-of-foot-health-in-merinosHead Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
For our third instalment of ESMO 2025, we explore lung cancer in all its glory, including small cell, mesothelioma and non-small cell lung cancer.Studies:DeLLphi-303SOHO-01ALBATROSPAULIENDREAM3ROptiTROP-Lung04For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
The gals are back this week and we're talking about rates caps, pre-election announcements, regional council reforms and resignations. It's the end of year and everyone is feeling a 'bit tired and a bit ratty' including our politicians. Yass Queen goes to Matt Doocey for changes to the way we record stillbirths. Beehave Mate goes to MSD for breaching the privacy of survivors of state abuse in care.
This episode covers: Cardiology This Week: A concise summary of recent studies DAPT: how short is too short Obesity and atrial fibrillation Milestones: COURAGE Host: Emer Joyce Guests: Carlos Aguiar, Steffen Massberg, Prash Sanders Want to watch that episode? Go to: https://esc365.escardio.org/event/2178 Want to watch that extended interview on dual antiplatelet therapy (DAPT) and shortening its optimal duration, go to: https://esc365.escardio.org/event/2178?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Emer Joyce, Nicolle Kraenkel and Steffen Massberg have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Prashanthan Sanders has declared to have potential conflicts of interest to report: advisory board representative University of Adelaide, Medtronic, Boston Scientific, CathRx, Abbott and Pacemate as well as research grants for University of Adelaide: Medtronic, Abbott, Boston Scientific, Becton Dickson. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Peter Boockvar, Chief Investment Officer at OnePoint BFG, joins the MSD airwaves once again for a breakdown of the potential dynamics of the Japanese bond market. With the Japanese central bank in the precipice of raising rates and the US Federal Reserve potentially cutting rates, the two decisions could have implications on the yen carry trade.
Frank Cappelleri of Capp Thesis walks MSD listeners through a number of charts which helps breakdown the latest headline moves. Frank covers the S&P first, but then moves ahead with gold, gold miners, silver, silver miners and bitcoin. Link to video: https://youtu.be/f6fSBo0mrLo
Episode 4 of our monthly GU Cast Journal Club and today we focus on two important papers in prostate cancer diagnostics and bladder cancer surgery. The PRECISION NEJM paper 2018 is a landmark publication which defined the role of mpMRI in early detection, and changed practice in many countries. The EB-StaR trial should also change practice after its European Urology 2024 publication, but has it??!We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. A very lively discussion!! Links to papers below:1. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis NEJM 20182. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial Eur Urol 2024GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant.Even better on our YouTube channelAbout GU Cast Journal Club:Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology. The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner. The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
On this week's episode, Tim Gole shares how sheep farmers can increase their profits by shifting from responding to problems to preventing them in the first place.Tim runs ForFlocksSake, a vet-based sheep consultancy company. After a lightbulb moment during the drought, Tim became a self-confessed sheep fanatic.With both Tim and Mark clearly in their element, they spend nearly an hour talking all things sheep. They discuss lifetime ewe programs, scanning strategies, the use of genetics to make production easier and more profitable, and the benefits and drawbacks of EID. They also cover reproductive efficiency, worm control lessons and lots of other sheep-related topics. Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
John Black, CEO of Aldebaran Resources, joins MSD today to discuss the news out this week that Nuton has decided to terminate its option agreement with the Altar Project in Argentina. John talks about the market reaction and how the company's story has not changed with the news. Work on the ground continues as planned, which included 4 drill rigs for resource conversion drilling and geotechnical work.
ESMO 2025 continues this week with coverage including early breast cancer, metastatic breast cancer and gynaecological malignancies. A mammoth episode covering giants and pioneers of the oncology world.Studies:SOLTI-RIBOLARISPOSITIVEmonarchE:DESTINY-Breast11evERAASCENT-03TROPION-Breast02 trialROSELLADICE trialENGOT-ov65/KEYNOTE-B96 studyROSELLAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Run it Red 127 is here - 88 tracks deep and featuring music from Oscar Mulero, Kerrie, Kr!z, R.M.K & Jamie Anderson, Jen Cruz, Elisa Bee and many more. As always full tracklist is below, so please check out the artists and labels! Hit the charity links if you can, too...
The names of five people seeking compensation for sexual abuse in state care were published online in a privacy breach by the Ministry of Social Development. The ministry has removed the link to documents naming the five, but Google searches of the names were still bringing up the MSD information in the search engine's AI summary as of yesterday morning. The ministry has apologised and says the breach was due to human error. Our reporter Jimmy Ellingham has the story, and a warning, this report contains references to suicide.
What do the genetics of tail length and the genetics of semen quality have in common? Not much, except that our guest, Marnie Hodge, Sheep Genetics Senior Development Officer, has researched them both.Tail length is moderately to highly heritable, but in her research, Marnie found that measuring tail length in centimetres versus a scored system gives you far more accuracy and picks up significantly more genetic variation, which means faster rates of genetic gain if you're selecting for it.But what's actually changing when tails get shorter? Are we dropping vertebrae or just shortening bones? And what about correlations with body structure? Marnie explains what we know, what we don't, and why we don't have a tail length breeding value quite yet. On the opposite end of the scale, as with all reproduction traits, semen quality is lowly heritable. Marnie's research, "Heritability and Genetic Parameters for Semen Traits in Australian Sheep", showed that most of the variation in AI success wasn't down to motility, but more down to the variation in ewe management on each farm. So what does that mean for the establishment of a potential future breeding value? Marnie explains on the podcast. Plus Marnie gives us some updates on what's coming from Sheep Genetics and the combined analysis.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
Diana Haneski and Dione Mila share their expertise and best practices (as well as resources!) for supporting student volunteers in K-12 school libraries. ALA Book Dione Mila IG @LibraryHubLife My monthly newsletter Linkedin From Learners to Leaders: Empowering Student Volunteers in the School Library | All4Ed E258 Emotional Support Librarian Diana Haneski @MSDlibrarymedia @dhaneski @RiversTales River our MSD therapy dog Newsletter MSD Media Center I Love My Librarian Award Lemony Snicket Prize for Noble Librarians Who Face Adversity HOPE Animal-Assisted Crisis Response Wakelet: Mindfulness in the Media Center E257 Building a Brand ALA: Guidelines for Authors
Kiran Patankar is the recently appointed CEO of Maple Gold Mines and he joined MSD to close out our coverage of the DGM in Frankfurt. Kiran shares some insights on renewing exploration activities at the Douay Gold project and the Joutel Gold Project. He talks about bringing new institutions and investors into the story to re-emerge the projects into the forefront of the investment community. Since the interview, the company did announce a 30,000m Phase II drill program.
This episode covers: Cardiology This Week: A concise summary of recent studies 'ChatGPT, MD?' - Large Language Models at the Bedside Management decisions in myocarditis Statistics Made Easy: Mendelian randomisation Host: Emer Joyce Guests: Carlos Aguiar, Folkert Asselbergs, Massimo Imazio Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Massimo Imazio, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Emer Joyce Guest: Folkert Asselbergs Want to watch that episode? Go to: https://esc365.escardio.org/event/2179 Want to watch that extended interview on 'ChatGPT, MD?': Large Language Models at the Bedside? Go to: https://esc365.escardio.org/event/2179?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Folkert Asselbergs, Yasmina Bououdina, Emer Joyce, and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. E mma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Rick Van Niewenhuyse, CEO of Contango Ore, connects with MSD following the announced record-high income from operations totaling $25M for the quarter. Rick talks about managing the company's debt and using the capital manage it hedges required from a previous financing. Rick also discusses the development of Lucky Shot and how that will be a key asset to bring the company's productin to 100koz per year.
A welfare expert says one of the Government's grants is a good idea in principle. The Taxpayers' Union has revealed the business start up grant has dished out $38 million with little to show for it. Documents retrieved through the Official Information Act show hundreds of the recipients struggled and returned to a benefit within two years. Former Welfare Expert Advisory Group member Phil O'Reilly told Mike Hosking the execution was woefully bad. He says the problem is MSD spent far too much and there wasn't enough mentoring or measuring of outcomes. LISTEN ABOVE See omnystudio.com/listener for privacy information.
How simple rotations and tight feed management lift whole farm performance.Mark chats with Bevan Ravenhill, WA General Manager for Lawson Angus WA, to talk about what really drives a productive grazing business. Bevan grew up on a dairy farm, and that early training in grass, rotation, and pressure has shaped the way he now runs sheep and beef across a mixed enterprise.Bevan explains how a simple rotation, tight feed management and a focus on leaf stage have transformed grass utilisation on the farm. He talks through how their accelerated lambing system works in practice, why confinement feeding has become such a reliable tool, and how silage underpins the whole engine when feed becomes tight.On the cattle side, Bevan shares the shift to moderate, efficient Angus cows and the lessons learnt from years of collecting real on-farm data. He digs into maternal efficiency, cow size, raw phenotypes and why consistency matters more than chasing extremes. They also cover spring calving, OptiWeigh and the role of pressure testing cattle rather than compensating for them.Tune in to hear some great insights from someone who has spent a lifetime thinking about how to turn grass into kilograms.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
After a short break for some pretty major life changes (more details in the episode), Josh and Michael return to tackle the best and brightest of ESMO 2025. With support from MSD, our dynamic duo play host to the inaugural Oncology for the Inquisitive Mind Awards. Today, they look at studies in pre-clinical science, supportive care and rare cancers to find their favourite studies amidst the goldmine that was this year's European Oncology Extravaganza.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Virtual participation with ESMO was provided by MSD. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
From the Zurich Precious Metals Summit, MSD's Trevor Hall sits down with Florian Grummes and John Feneck to a general discussion on the precious metals market and the precious metals equities. John shares insights into the macro narratives driving the rebound in gold, including White House news and trade negotiations. Florian provides some insights into forecasts he is seeing for gold and silver.This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at revival-dash-gold.comVizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at https://vizslasilvercorp.com/Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at equinoxgold.com Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com
L'azienda farmaceutica statunitense Merck & Co. (nota nel resto del mondo come MSD) ha annunciato i risultati molto promettenti di un nuovo farmaco che insieme alle statine contribuisce alla riduzione del colesterolo, con i partecipanti ai test clinici che hanno visto ridursi i livelli di LDL (il “colesterolo cattivo”) fino al 60 per cento in modo stabile per un anno. Ma che cosa rende “cattivo” o “buono” il colesterolo? E quella storia dei limiti cambiati anni fa per vendere più farmaci è vera? È tempo di una guida rapida. Ci spostiamo poi nell'Artico per una scoperta cosmica, eppure molto terrestre, che potrà aiutarci negli studi sul riscaldamento globale. Infine, ci occupiamo di multilinguismo e mente giovane. Il link per abbonarti al Post e ascoltare la puntata per intero. Leggi anche: – La pillola di Merck per ridurre il colesterolo in aggiunta alle statine dà risultati paragonabili alle iniezioni – Cattiva prevenzione. I pericoli del consumismo sanitario di Roberta Villa – Statine sconsigliate in TV – Integratori a base di riso rosso fermentato: un'analisi delle sospette reazioni avverse – La polvere cosmica rivela i cambiamenti dinamici nella copertura di ghiaccio marino dell'Artico centrale negli ultimi 30.000 anni – Gli articoli del Post sulla COP30 – Il multilinguismo protegge dall'invecchiamento accelerato Learn more about your ad choices. Visit megaphone.fm/adchoices
In September, Fuerte Metals announced the acquisition of the Coffee gold project in Yukon from Newmont. CEO Tim Warman joined MSD to shares some insights from the deal and the acquisition. We talk about the entrance of the company in Yukon, its relationship with the communities and first nations, and how the company will continue to develop the project throughout 2026.
Shaun Heinrichs of 1911 Gold joins MSD today for an introduction to the company and its True North Gold Project. He shares some insights into the consolidated land package totaling more than 61,647 hectares within and adjacent to the Archean Rice Lake greenstone belt in Manitoba. We discuss the strategies for exploration and mine development. He also shares his commentary on recent market moves.
Ever wondered what it takes to build a succesfull seedstock buisness from the ground up? Well, this is the podcast for you. This week, Mark chats with Jasmine and Hayden Green, owners of Summit Livestock, about how they built their Angus and Limousin seedstock business from the ground up (and the challenges they faced), the importance of crossbreeding for production, how they balance phenotype with data, and the challenges of getting started without your own land.Jasmine and Hayden have built a successful dual-breed business, and they run us through the decision to run both breeds and the advantages of crossbreeding for both themselves and their clients. They also discuss the importance of embryo transfer in expanding their herd while keeping genetic quality at the forefront.Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
This episode covers: Cardiology this Week: A concise summary of recent studies Lp(a) - What to expect in the very near future Myocardial infarction in older and frail adults Mythbusters: is beetroot good for your heart? Host: Rick Grobbee Guests: JP Carpenter, Vijay Kunadian, Erik Stroes Want to watch that episode? Go to: https://esc365.escardio.org/event/2177 Want to watch that extended interview on Lp(a), go to: https://esc365.escardio.org/event/2177?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Nicolle Kraenkel, Vijay Kunadian and Erik Stroes have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Accounting may not be every farmer's favourite topic, but it is one of the most powerful tools on the farm. This week's Head Shepherd guest, David Egerton-Warburton, explains why.Raised on a sixth-generation farm in Kojonup, Western Australia, David learned early that every on-farm decision ties back to sound business practice. His father, Kent, founded Agrimaster in 1981, bringing farm records into the computer age long before most households had a computer, and David and his wife have been joint CEOs since 2001.David and Mark Ferguson discuss budgeting, risk control and decision making, and why financial literacy separates good farmers from great farming businesses. As David says, “The most successful growers aren't that much better from a production point of view… what we really see is the difference in the ability to take risks because they can control them.” Listen to the episode to learn how to turn your farm numbers into a roadmap for success and take control of the risks that matter.https://www.agrimaster.com.au/Head Shepherd is brought to you by neXtgen Agri International Limited. We help livestock farmers get the most out of the genetics they farm with. Get in touch with us if you would like to hear more about how we can help you do what you do best: info@nextgenagri.com.Thanks to our sponsors at MSD Animal Health and Allflex, and Heiniger Australia and New Zealand. Please consider them when making product choices, as they are instrumental in enabling us to bring you this podcast each week.Check out Heiniger's product range HERECheck out the MSD range HERECheck out Allflex products HERE
What if you could grow your dental practice without ever compromising patient experience? In this episode, host Jordin McEntire talks with Dr. Rania Saleh, DDS, MSD, Founder and CEO of Oryx Dental Software. Dr. Rania shares how her journey as a practicing dentist revealed the gaps in patient care, communication, and team efficiency that inspired her to build Oryx — a cloud-based dental software designed by dentists, for dentists. She opens up about the challenges of leading innovation in an industry resistant to change, how Oryx helps teams shift from reactive to proactive dentistry, and why staying close to your patients and your purpose is the key to lasting growth.
Mining Stock Daily welcomes Michael Green to delve into the broken equity structure and its profound implications for the metals and miners audience. Green outlines his serious concerns regarding the explosive growth of passive investing, estimating that north of 50% of the total market capitalization is now contained within passive vehicles. This structural change creates a passive mandate bias toward large-cap concentration, which specifically distorts the valuations and liquidity of smaller cap resource and precious metals stocks. He illustrates how incremental passive flows disproportionately magnify the price impact on the largest stocks while shrinking buy orders for smaller index components, creating a momentum reinforcement vehicle that exacerbates market bifurcation. The discussion also covers the dangers of highly leveraged instruments like 2x-3x ETFs and the motivations behind their creation, which often caters to speculative demand rather than thoughtful investment policy. Finally, Green links current financial behavior and political inaction to historical cycles, drawing an analogy between the contemporary failure of American systems and the collapse of the Roman Republic, suggesting the current gold rally may signal a flight from systemic risk rather than just inflation.Inquire more about the MSD discount for to Mike's Substack HEREThis episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at revival-dash-gold.comVizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at https://vizslasilvercorp.com/Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at equinoxgold.com Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com
This episode covers: Cardiology This Week: A concise summary of recent studies Arrhythmias in cardiac amyloidosis Taking the 'O' out of HOCM: managing LVOT obstruction Snapshots Host: Susanna Price Guests: Carlos Aguiar, Stephanie Schwarting, Ahmad Masri Want to watch that episode? Go to: https://esc365.escardio.org/event/2176 Want to watch that extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Ahmad Masri has declared to have potential conflicts of interest to report: research grants from Pfizer, Ionis, Attralus, Cytokinetics and Janssen. Consulting fees from Cytokinetics, BMS, BridgeBio, Pfizer, Ionis, Lexicon, Attralus, Alnylam, Haya, Alexion, Akros, Edgewise, Rocket, Lexeo, Prothena, BioMarin, AstraZeneca, Avidity, Neurimmune, and Tenaya. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
Host: Susanna Price Guest: Stephanie Schwarting Want to watch the episode? Go to: https://esc365.escardio.org/event/2176 Want to watch the extended interview on Arrhythmias in Cardiac Amyloidosis? Go to: https://esc365.escardio.org/event/2176?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Stephanie Schwarting has declared to have potential conflicts of interest to report: advisory board for Alnylam, Bayer, Pfizer; principal investigator in trials sponsored by Alexion, Novo Nordisk and Intellia. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.
We discussed a few things including:1. Their career journeys2. Merck's venture strategy and GHIF story3. MSD Idea Studios4. CVC landscape and trends5. Outlook for pharma and innovationBill has led MSD Global Health Innovation (GHI) since 2010, playing a strong role in the US company's transition a decade ago from general consumer pharmaceuticals to a focus on biopharmaceuticals and oncology.With 45 portfolio companies and about 80% having commercial agreements with MSD, His approach of always seeking to understand and solve the parent company's core challenges has proven successful.Last year, the fund expanded beyond the US, launching two accelerator programms, one in Berlin covering central Europe and one in Singapore covering 10 Asian countries. The accelerators will also invest at an earlier stage than the growth stage-focused core GHI fund has typically done.Both in the US and abroad, GHI is focused on four key areas of pharma services: drug discovery, clinical development, supply chain and patient access.In drug discovery, Bill is particularly excited about AI and machine learning allowing drugs to be identified faster. The fund has invested in about 12 companies applying AI to biology, chemistry and vaccines in the past two years, with a belief that these technologies are on the cusp of a breakthrough.Clinical development is another critical focus, especially in patient diversity and trial management.The unit is also exploring supply chain innovations, with systems tracking raw materials coming in and finished goods going out, much like a “control tower at an airport”.A veteran of the venture capital sector, Bill maintains that corporate venture capital is becoming increasingly sophisticated. He believes corporate venture capital has now established itself as “part of the ecosystem of investing” and offers unique value that traditional investors cannot.----Joel is a seasoned executive with extensive experience in venture investments and strategic innovation within the healthcare sector. With a career spanning over two decades, he has held pivotal roles at renowned organizations like Merck, J&J, and JPMorgan, focusing on biotech, corp dev and health equity. He excels in bridging the gap between life sciences and digital health technology. He is a recognized advocate for diversity and inclusion, emphasizing health equity in his professional endeavors. #podcast #afewthingspodcast
MSD welcomes Bill Fleckenstein of Fleck Capital to dive into the markets, addressing the big sell-off in precious metals that followed Gold running up to $4,000 and Silver hitting $50. They explore the confusing narrative behind gold's recent outperformance, noting that its surge came despite events seeming "less bad" incrementally, suggesting it is catch-up and anticipation of future policy. Fleckenstein focuses on the risk of presidential control over the Federal Reserve, predicting policies like yield curve control, which he believes will likely be "negative for the dollar" and lead to "more inflation". This discussion leads to an analysis of the dangers posed by the desire of the "powers that be" to "run the economy hot," which inevitably leads to inflationary consequences and the dangerous misallocation of capital. Finally, they analyze the nature of the immediate correction, the hard sell-off experienced by the miners, and the philosophical debate over government acquisition of equity in critical mineral companiesOur second segment features Tom Woolrych with his keen eye to detail and 3D modeling of exploration stories. Tom walks through a few specific companies making headlines lately. You can watch that interview and his presentation HERE.This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at revival-dash-gold.comVizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at https://vizslasilvercorp.com/Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at equinoxgold.com Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com
Warwick Smith of American Pacific Mining connected with MSD's Michael McCrae to discuss the upcoming drill campaign at the Madison copper-gold porphyry project in Montana. Having now received a key drill permit in early October, this next phase of drilling will test large-scale porphyry and high-grade skarn targets with step-outs and deeper holes guided by decades of geologic mapping, geochemical sampling, geophysical surveying, and 3D structural modeling.
Barry Knapp of Ironsides Macro joined MSD today to provide his thoughts on why the last 25 bps cut by the FOMC under-shot the target to save small business, bank and the housing market. Barry also dives into some important data about the weakening labor market and historical data on capex buildout in the current economy.
Mining Stock Daily is thrilled to announce well-known resource reporter, Michael McCrae, is joining MSD as a new correspondent. We welcome Mike into the channel today. We have new drill results to report from Stellar AfricaGold, Intrepid Metals and Aton Resources. Fortuna Mining launch a new JV exploration deal with DeSoto. Both Collective Mining and NexGen announce financings. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at revival-dash-gold.comVizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at https://vizslasilvercorp.com/Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at equinoxgold.com Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com
Ben Pullinger of ATEX Resources joined MSD to discuss the updated mineral resource estimate for the Valeriano Project in Chile, which now includes the mineralization from the latest addition of the B2B Zone. The company also announced a new surface rights agreement surrounding the project. Ben talks about the importance of this agreement and what it means for the continued development.
© 2020-2025 Ivy Podcast Discovery LLC
